BioTime Form 8-K Oct 23 2007
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of
Report (date of earliest event reported): October
23, 2007.
BioTime,
Inc.
(Exact
name of registrant as specified in its charter)
|
California
|
1-12830
|
94-3127919
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
6121
Hollis Street
Emeryville,
California 94608
(Address
of principal executive offices)
(510)
350-2940
(Registrant's
telephone number, including area code)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
[ ] Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
[ ] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Statements
made in this Report that are not historical facts may constitute forward-looking
statements that are subject to risks and uncertainties that could cause actual
results to differ materially from those discussed. Such risks and uncertainties
include but are not limited to those discussed in this report and in BioTime's
Annual Report on Form 10-KSB filed with the Securities and Exchange Commission.
Words such as “expects,” “may,” “will,” “anticipates,” “intends,” “plans,”
“believes,” “seeks,” “estimates,” and similar expressions identify
forward-looking statements.
Section
5 - Corporate Governance and Management
Item
5.02 - Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers
The
employment of Jeffrey B. Nickel, Ph.D, Vice President of Business Development
and Marketing, terminated on October 23, 2007. Dr. Nickel may provide
consulting services to BioTime from time to time in the future.
On
October 23, 2007 BioTime announced that Robert W. Peabody, CPA, has joined
BioTime as Senior Vice President and Chief Operating Officer. Mr.
Peabody will oversee the operating departments of BioTime and will head
BioTime’s efforts to obtain research funding grants from private and public
sources, including the California Institute for Regenerative Medicine, to help
finance BioTime’s
entry into the field of regenerative medicine and stem cell research.
Prior
to
joining BioTime, Mr. Peabody served as Vice President-Grant Administration
for
Advanced Cell Technology, Inc and also served on their Board of Directors from
1998 to 2006.
Further
information concerning Mr. Peabody can be found in the press release filed
as
Exhibit 99.1
Section
7 - Regulation FD
Section
7.01 - Regulation FD Disclosure
The
press
release filed as Exhibit 99.1 is incorporated by reference.
Section
9 - Financial Statements and Exhibits
Item
9.01- Financial Statements and Exhibits.
|
Exhibit
Number
|
|
Description
|
| |
|
|
|
99.1
|
|
Press
release dated October 23, 2007
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
BIOTIME,
INC.
|
| |
|
| |
|
|
Date: October
23, 2007
|
By
/s/
Judith
Segall
|
| |
Vice
President & Secretary
|
| |
Member,
Office of the President
|
|
Exhibit
Number
|
|
Description
|
| |
|
|
|
99.1
|
|
Press
release dated October 23, 2007
|
3